4.8 Review

Leukotriene receptors as potential therapeutic targets

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 128, 期 7, 页码 2691-2701

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI97946

关键词

-

资金

  1. Ministry of Education, Culture, Sports, Science and Technology (MEXT)/Japan Society for the Promotion of Science KAKENHI [15H04708, 15H05897, 18H02627, 17K082, S29229003]
  2. AMED GAPFREE Program [17ak0101043h0003]
  3. Takeda Science Foundation
  4. Naito Foundation
  5. Mitsubishi Foundation
  6. Foundation of Strategic Research Projects in Private Universities from MEXT [S1311011]
  7. Institute for Environmental and Gender-Specific Medicine
  8. Shimadzu Co. Ltd., Japan
  9. ONO Pharmaceutical Co.
  10. Grants-in-Aid for Scientific Research [15H04708, 18H02627, 15H05897] Funding Source: KAKEN

向作者/读者索取更多资源

Leukotrienes, a class of arachidonic acid-derived bioactive molecules, are known as mediators of allergic and inflammatory reactions and considered to be important drug targets. Although an inhibitor of leukotriene biosynthesis and antagonists of the cysteinyl leukotriene receptor are clinically used for bronchial asthma and allergic rhinitis, these medications were developed before the molecular identification of leukotriene receptors. Numerous studies using cloned leukotriene receptors and genetically engineered mice have unveiled new pathophysiological roles for leukotrienes. This Review covers the recent findings on leukotriene receptors to revisit them as new drug targets.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据